SMi Pharma-Masterclass: Pricing and Reimbursement Strategies

Sept. 14, 2010 - PRLog -- 6th December 2010, Central London, UK

No single factor influences profits more than price.  Accordingly, it is imperative to develop an effective pricing strategy early in the product life cycle. However, an optimal price for reimbursement / market access in one market may not be optimal in others and the pervasiveness of international price referencing and parallel trade creates pressures for price convergence often at sub-optimal levels in key markets. Moreover, health technology assessment (HTA) agencies have taken on increasingly important roles in assessing clinical and cost effectiveness and their assessments have spawned a new environment of risk sharing agreements and patient access schemes.

Who is leading this MasterClass?

Neil Palmer, President & Principal Consultant, PDCI Market Access

Neil Palmer is President and Principal Consultant of PDCI Market Access Inc (PDCI) a leading pricing and reimbursement consultancy founded as Palmer D'Angelo Consulting Inc (PDCI) in 1996.  In addition to PDCI, Neil has worked with RTI Health Solutions, the Patented Medicine Prices Review Board (PMPRB), the Health Division of Statistics Canada and the research group of the Kellogg Centre for Advanced Studies in Primary Care in Montreal. He has more than 20 years of experience in pharmaceutical pricing and reimbursement and is a frequent speaker at pharmaceutical conferences in North America and Europe.



Martin Brown, Head of Health Economics and Outcomes Research, Novartis Pharmaceuticals UK Limited

Martin Brown has over twelve years' experience working in the health economic and outcomes research field in the pharmaceutical and biopharmaceutical industry. The majority of his experience has been in global health economic/outcomes departments at Pfizer and UCB, where he was the Global Head of Health Economics. These roles involved providing advice and recommendations to clinical development teams in order to ensure that the necessary clinical and cost-effectiveness evidence was generated for healthcare guidance and reimbursement bodies.

TO VIEW THE FULL PROGRAMME AND FOR THE OPPORTUNITY TO REGISTER ONLINE TODAY PLEASE VISIT: http://www.smi-online.co.uk/10pnr-mc1.asp

Why should you attend this event?

Upon completion of this MasterClass, attendees will have an understanding of:

Global pricing and reimbursement elements and principles
Pricing theory and research methods
Latest information on the expected changes in the UK (NICE, PPRI, SMC)
P&R/HTA in major EU markets and Canada
Launch sequencing, price corridors

# # #

SMi have had an established portfolio of Pharmaceutical, Defence, Energy, Finance and PPP/PFI events running since 1993. We are at the forefront of linking businesses with information, organising over 150 Conferences, Workshops and Masterclasses every year. All our events are research driven and highly targeted towards senior level professionals, designed to help you make informed decisions and remain at the cutting edge of business information.

SMi Conferences offer you an unrivalled opportunity to network within your area of business and our Workshops and Masterclasses provide an intimate, interactive forum in which to learn about the latest techniques and developments.